ALFA Finder
India's fastest NSE & BSE filing alerts on Telegram, filtered to the stocks you hold
Telegram alerts
alfafinder.com →
ALFA Filings
Every announcement, straight from the exchange
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
Announcement type
Time
36 announcements
FDC Ltd has received a favorable income tax refund order of Rs. 20.71 Crore for AY 2013-14. The jurisdictional Assessing Officer issued the refund following a successful appeal.
FDC Limited received a favorable income tax refund order for Assessment Year 2016-17. The Assistant Commissioner of Income Tax determined an aggregate refund of Rs. 14.20 Crore.
FDC received tax orders giving an aggregate refund of Rs.37.22 Crore for AY 2014-15 and AY 2012-13. The refund follows favourable CIT(A) orders on the company's appeals.
FDC Limited reports Q2 FY27 revenue of Rs. 572 crore, up 21%, and EBITDA of Rs. 64 crore. Domestic formulations grew 22.6% and international formulations rose 28.5%.
FDC Ltd reported revenue from operations of ₹572.1 Cr (+21.0% YoY) and net profit of ₹49.1 Cr (+72.9% YoY) for Q2 FY27.
FDC's board approved a buyback of up to ₹120 Crore at ₹500 per share via tender offer. The record date is November 13, 2026.
FDC Limited scheduled a board meeting for October 27, 2026, to discuss financial results and a proposed buyback.
FDC Ltd has submitted its quarterly shareholding pattern for the period ended September 30, 2026, as per regulatory requirements.
FDC Limited issued a corrigendum to its 86th AGM notice, correcting the e-voting cut-off date to September 17, 2026. This also updates the book closure dates.
Promoter Nandan Mohan Chandavarkar gifted 50,30,086 shares of FDC Ltd via off-market inter-se transfers. His personal stake decreased from 3.10% to 0.01%.
FDC Limited submitted its Business Responsibility and Sustainability Report for the financial year 2025-26. This filing complies with regulation 34 of SEBI (LODR) regulations.
FDC Limited has filed its Annual Report for the financial year 2025-26, and the 86th AGM is scheduled for September 24, 2026.
FDC Limited issued a notice for its 86th Annual General Meeting to be held on September 24, 2026. The meeting includes agenda items for financial statement adoption.
FDC Limited has scheduled its 86th Annual General Meeting for September 24, 2026, to approve financial statements and ratify the cost auditor's remuneration.
FDC Limited received an interim stay from the Delhi High Court regarding an FSSAI notice, allowing 8 months to exhaust existing stock with specific product labels.
FDC Limited's subsidiary, FDC International Limited, received marketing authorization from MHRA, UK for Atropine 1.0% eye drops. This regulatory approval enables product commercialization in the United Kingdom.
FDC Limited reported its Q1 FY27 consolidated results in a press release. The company highlighted Revenue of Rs. 668 crore and PAT of Rs. 132 crore.
FDC Ltd reported revenue from operations of ₹667.7 Cr (+3.0% YoY) and net profit of ₹132.5 Cr (+9.2% YoY) for Q1 FY27.
FDC Limited scheduled a board meeting for August 5, 2026. The board will consider the quarterly unaudited financial results for June 2026.
Mohan Anand Chandavarkar Trust acquired 26,70,316 shares (1.64%) of FDC Limited through an off-market gift. This inter-se transfer occurs within the promoter group.
Promoter Nandan Mohan Chandavarkar gifted 50,30,086 shares (3.09% stake) to family trusts. The off-market inter-se transfer reduces his direct holding to 0.01%.
Maharashtra FDA officials seized stock of FDC's 'Enerzal' product due to alleged misbranding. The company reports no material financial impact and plans legal recourse.
FDC Limited shareholders approved the appointment of Mr. Kishore Mukund Saletore as an Independent Director. The resolution passed with a 99.77% majority via postal ballot.
FDC Limited filed its Annual Secretarial Compliance Report for the financial year 2026. The auditor reported full compliance with SEBI regulations with no deviations or penalties.
FDC Limited reported FY26 revenue of ₹2,171 Crore, reflecting 3.0% annual growth. Q4 performance was robust with 18.9% revenue growth and significantly improved EBITDA margins.
FDC Limited reported Q4 FY26 revenue of ₹585 Crore, achieving 18.9% Y-o-Y growth. Robust performance across domestic and export segments drove significant margin expansion to 18.2%.
FDC Ltd reported revenue from operations of ₹584.8 Cr (+18.9% YoY) and net profit of ₹103.4 Cr (+167.2% YoY) for Q4 FY26.
FDC Limited reported annual standalone total income of ₹2,237.33 Crore for FY2026. The board also re-appointed cost and tax auditors for the upcoming financial year.
FDC Limited scheduled a board meeting for May 27, 2026, to approve audited financial results. This provides advance notice for upcoming performance disclosures.
FDC Limited received U.S.FDA ANDA approval for Cefixime Oral Suspension USP in two strengths. This regulatory milestone enables the company to market these products in the US.